Related Experiment Videos
Revised approach for identification and detection of ampicillin and vancomycin resistance in Enterococcus species by
P C Iwen1, D M Kelly, J Linder
1Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha 68198-6495, USA.
Abstract:
The frequency of antimicrobial agent-resistant enterococci is increasing, making accurate identification and screening for susceptibility essential. We evaluated the ability of MicroScan Positive Breakpoint Combo Type 6 panels (Dade MicroScan Inc., West Sacramento, Calif.) to identify Enterococcus species and to detect ampicillin and vancomycin resistance. A total of 398 well-characterized Enterococcus isolates from two institutions were inoculated into MicroScan panels, into conventional biochemical assays, and into ampicillin and vancomycin agar dilution media. Resistance was verified by the broth macrodilution method. MicroScan panels accurately detected resistance to ampicillin in 132 of 132 enterococcal isolates, while three isolates for which the MICs were < 16 micrograms/ml were classified incorrectly by MicroScan panels as resistant. No beta-lactamase-producing enterococci were detected. All 64 isolates showing resistance to vancomycin (MICs > or = 32 micrograms/ml) were correctly classified by MicroScan panels. Seven isolates for which the vancomycin MICs were 8 and 16 micrograms/ml were incorrectly classified as susceptible by MicroScan panels, while eight isolates for which the MICs were 4 micrograms/ml were incorrectly labeled as intermediate. Fourteen of these 15 isolates were subsequently identified as motile enterococci. Overall, there were three major errors in susceptibility testing for ampicillin and 15 minor errors for vancomycin. Conventional testing confirmed the identity of 181 Enterococcus faecalis isolates, 157 E. faecium isolates, and 60 isolates of other species; however, 56 of these 60 isolates were misidentified by the MicroScan panels. After recognition of this problem, a revised approach which included tests for pigment, motility, and sucrose fermentation was devised. In combination with these additional assays, the conventional MicroScan panels accurately identified the 56 originally misidentified isolates. In summary, the ability of MicroScan panels to detect vancomycin and ampicillin resistance in enterococci was confirmed. Our study found that the inability of MicroScan panels to identify enterococci other than E. faecalis and E. faecium can be compensated for by the addition of standard assays.
Insights
Antimicrobial resistance in enterococci is rising. MicroScan panels accurately detect ampicillin and vancomycin resistance but struggle with species identification, requiring additional assays for accurate results.
Area of Science:
- Clinical Microbiology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Increasing prevalence of antimicrobial-resistant enterococci necessitates reliable diagnostic methods.
- Accurate identification and susceptibility testing are crucial for effective treatment of enterococcal infections.
Purpose of the Study:
- To evaluate the MicroScan Positive Breakpoint Combo Type 6 panels for Enterococcus species identification.
- To assess the panels' ability to detect ampicillin and vancomycin resistance in enterococci.
Main Methods:
- 398 Enterococcus isolates were tested using MicroScan panels and conventional biochemical assays.
- Antimicrobial resistance was verified by broth macrodilution and agar dilution methods.
- A revised approach incorporating pigment, motility, and sucrose fermentation tests was developed.
Main Results:
- MicroScan panels accurately detected ampicillin resistance in all tested isolates.
- All vancomycin-resistant isolates (MICs ≥ 32 µg/mL) were correctly classified.
- Species identification was problematic, with 56 of 60 non-E. faecalis/E. faecium isolates misidentified; this was corrected with additional assays.
Conclusions:
- MicroScan panels demonstrate reliable detection of ampicillin and vancomycin resistance in enterococci.
- Species identification limitations of MicroScan panels can be overcome by incorporating standard biochemical tests.
- Combined methods ensure accurate identification and susceptibility profiling for improved patient management.